Health
Healthy Returns: More than 50 million privately insured adults could be eligible for GLP-1 drugs
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future […]
Read More
Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment
Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease. But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others. Meeks, an English professor based in Ellisville, Mississippi, […]
Read More
Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock
A sign with the company logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024. Scott Olson | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Earlier this […]
Read More
Abbott launches its first over-the-counter continuous glucose monitor in the U.S.
A man wearing Abbott’s Lingo biosensor. Courtesy of Abbott Abbott Laboratories announced Thursday its over-the-counter continuous glucose monitor Lingo is available in the U.S. starting at $49. Lingo is part of an emerging class of consumer-friendly biosensors that people can use to learn how their bodies respond to food, exercise, sleep and stress. These devices, […]
Read More
GE Healthcare shows signs of life, but a lingering uncertainty keeps us on the sidelines
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. More weakness: There’s been a couple attempts at a rally Wednesday, but stocks are still mostly lower in the second session of September after a rough […]
Read More
We’re taking a nearly 300% profit on a hot drug stock — adhering to an investing rule to live by
Shortly after the opening bell, we’ll be selling 10 shares of Eli Lilly at roughly $958 each. Following Monday’s trade, Jim Cramer’s Charitable Trust will own 100 shares of LLY, decreasing its weighting to 2.85% from about 3.13%. Now that we are no longer restricted, we are selling some Eli Lilly shares. We downgraded Lilly […]
Read More
A journey inside Epic Systems’ mythical and sprawling campus, a world away from Wall Street
A sign that reads “Epic Intergalactic Headquarters” on campus. Epic Systems Dorothy Gale was right — the Land of Oz is not in Kansas. Rather, it’s nestled within the rolling green fields of Verona, Wisconsin, a town of nearly 16,400 people located about 10 miles southwest of the capital city of Madison. Verona is home […]
Read More
FDA authorizes Novavax’s updated Covid vaccine, paving way for fall rollout
A vial labelled “Novavax V COVID-19 Vaccine” is seen in this illustration taken January 16, 2022. Dado Ruvic | Reuters The Food and Drug Administration authorized Novavax‘s updated protein-based Covid vaccine for emergency use in people ages 12 and up on Friday, paving the way for the shot to compete with Pfizer and Moderna‘s jabs […]
Read More
Healthy Returns: What to know about the latest round of Pfizer, Moderna Covid vaccines
Moderna Covid-19 Vaccine mRNA 2024-2025 formula. Courtesy: Moderna A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. It’s that time of the year again. A new round of Covid shots is on its way to Americans. […]
Read More
Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply
Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to reach millions of patients without insurance coverage for the popular injection, such as those with Medicare. The move also aims to expand the supply of Zepbound in the U.S. as demand skyrockets, […]
Read More